Brokerages Set Cencora, Inc. (NYSE:COR) Price Target at $367.75

Shares of Cencora, Inc. (NYSE:COR) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $367.75.

Several analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Evercore set a $360.00 price target on shares of Cencora in a research report on Wednesday, April 8th. Citigroup dropped their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Robert W. Baird cut their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th.

Cencora Price Performance

COR stock opened at $309.67 on Friday. Cencora has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a market capitalization of $60.25 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58. The business has a 50 day simple moving average of $284.52 and a 200-day simple moving average of $316.47.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the business posted $4.42 EPS. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts anticipate that Cencora will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio is 18.40%.

Cencora announced that its Board of Directors has initiated a share buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Cencora

In other news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, with a total value of $148,626.50. Following the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.38% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. raised its position in Cencora by 160.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Norges Bank acquired a new position in shares of Cencora in the 4th quarter valued at $822,506,000. Marshall Wace LLP grew its holdings in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after purchasing an additional 1,241,186 shares during the period. Finally, Viking Global Investors LP increased its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.